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Clinical trialThis double-blind, randomized, controlled study assessed the effect of esteriﬁed propoxylated glycerol
(EPG) on fat-soluble vitamins and select nutrients in human subjects. For 8 weeks, 139 healthy volunteers
consumed a core diet providing adequate caloric and nutrient intakes. The diet included items (spread,
mufﬁns, cookies, and biscuits) providing EPG (10, 25, and 40 g/day) vs. margarine alone (control). EPG
did not signiﬁcantly affect circulating retinol, a-tocopherol, or 25-OH D2, but circulating b-carotene
and phylloquinone were lower in the EPG groups, and PIVKA-II levels were higher; 25-OH D3 increased
but to a lesser extent than the control. The effect might be related to EPG acting as a lipid ‘‘sink’’ during
gastrointestinal transit. No effects were seen in secondary endpoint measures (physical exam, clinical
pathology, serum folate, RBC folate, vitamin B12, zinc, iron, calcium, phosphorus, osteocalcin, RBP, intact
PTH, PT, PTT, cholesterol, HDL-C, LDL-C, triglycerides). Gastrointestinal adverse events (gas with dis-
charge; diarrhea; oily spotting; oily evacuation; oily stool; liquid stool; soft stool) were reported more
frequently by subjects receiving 25 or 40 g/day of EPG. In general, the incidence and duration of these
symptoms correlated directly with EPG dietary concentration. The results suggest 10 g/day of EPG was
reasonably well tolerated.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction 2. Materials and methodsEsteriﬁed propoxylated glycerols (EPGs) represent a family of
fat- and oil-like substances, resembling triglycerides in structure
and appearance, but modiﬁed to prevent or limit their digestion
when consumed in food. They consist of multiple propylene glycol
units inserted between the glycerol and fatty acid moieties of fats
and oils. Their poor absorption results in a low- to no-calorie pro-
ﬁle when substituted for fat in the diet.
The present study evaluated the possible effects of dietary EPG
on the circulating levels of fat-soluble vitamins and select nutri-
ents, along with its tolerability, when administered to healthy vol-
unteers for 8 weeks.This study was sponsored by ARCO Chemical Company, Newton
Square, Pennsylvania, and conducted at Chicago Center for Clinical
Research, Chicago, Illinois, between January and March of 1997.
The study was conducted under the principles of the World Medi-
cal Assembly Declaration of Helsinki and its amendments. The
study protocol, amendments, and written informed consent were
reviewed and approved by the Schulman Associates Institutional
Review Board, Inc. (Cincinnati, OH), in conformance with 21 CFR
50 and 21 CFR 56. A signed informed consent statement was
obtained from each subject at the ﬁrst visit prior to any study
procedures.2.1. Selection of study subjects
Generally healthy male and female volunteers age 18–50 years
within10%/+30% of the ideal body weight for height, based on the
Metropolitan Life Insurance Company tables, 1983 without signif-
icant abdominal disorders.
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The study, which lasted 8 weeks, was conducted using a dou-
ble-blind, randomized and controlled design with four parallel
groups. To maintain balance among the treatment groups, the
groups were stratiﬁed by age (18–29 and 30+), sex, and estimated
caloric need (1800–2400 and 2600–3000). At least 139 healthy
adult male and female eligible subjects were enrolled and were
randomized to one of the following treatment groups: control
(ordinary triglycerides from margarine); 10 g/day EPG (EPG 10);
25 g/day EPG (EPG 25); or 40 g/day EPG (EPG 40).
For the evaluation of the response to treatment, the following
outcome variables were measured at baseline and regular
intervals:
 Primary Endpoints
Serum b-carotene, retinol (vitamin A), a-tocopherol (vitamin
E), 25-OH D2 (vitamin D, ergocalciferol), 25-OH D3 (vitamin
D, cholecalciferol), phylloquinone (vitamin K1), and PIVKA-
II (proteins induced in vitamin K absence).
 Secondary Endpoints
Changes from baseline in serum folate, RBC (red blood cell)
folate, vitamin B12, zinc, iron, calcium, phosphorus, osteocal-
cin, RBP (retinol-binding protein), intact PTH (parathyroid
hormone), PT (prothrombin time), PTT (partial thrombo-
plastin time), cholesterol, HDL-C (high-density lipoproteins),
LDL-C (low-density lipoproteins), and triglycerides.
Changes from baseline in urine concentrations of zinc,
sodium, potassium, creatinine, calcium, and phosphorus.
Secondary endpoints also included tolerability and nutrient
intake [% calories from fat (saturated, monounsaturated,
polyunsaturated), carbohydrate, and protein; a-tocopherol;
calcium; cholesterol; dietary ﬁber; energy; folacin; insoluble
and water-soluble dietary ﬁber; iron; phosphorus; potas-
sium; total protein; selenium; total carbohydrate; total fat
(saturated, monounsaturated, polyunsaturated); vitamin A;
vitamin B12; vitamin D; and zinc].
Tolerability was assessed by the incidence of 14 speciﬁc gas-
trointestinal adverse events: passing gas; gas with dis-
charge; abdominal bloat/cramp; heartburn; diarrhea;
constipation; urgency of bowel movement; fecal inconti-
nence; oily spotting; oily evacuation; oily stool; liquid stool;
soft stool; and hard stool.
2.3. Test material
The version of EPG tested in this study was EPG-05 HR/ST 45:55
[lot numbers 850308 and 900445]. EPG was incorporated into
spreads, mufﬁns, cookies and biscuits, prepared and coded so that
neither the subject nor the staff member administering the food
was aware of its composition.2.4. Treatment
From Days 1 through 56, study subjects received study meals
that incorporated two biscuits and two pats of spread (margarine
or EPG) at breakfast; one mufﬁn, one cookie, and one pat of spread
at lunch; and one biscuit, two cookies, and one pat of spread at din-
ner. These items were intended to provide a total of 0 (control), 10,
25, or 40 g of EPG daily, divided approximately equally among the
study meals (breakfast, lunch, and dinner on weekdays; brunch
and dinner on weekends). In an effort to maintain a stable body
weight for each subject, supplemental snacks were also provided,
as needed, as a source of additional calories. Drinks such as diet/
low-sodium soft drinks, regular, sparkling, and ﬂavored water were
provided for consumption off-site; water was consumed ad libitum.A ‘‘core diet’’ was developed to achieve target intakes of 80–
120% of the RDA for vitamins A, D, and K, b-carotene, folate, zinc,
iron, and calcium, and at the same time meet the different total
energy needs of the individual male and female subjects. The core
diet, which included the EPG food vehicles, provided 2200 kcal of
energy per day.
Because the core diet may not have satisﬁed the energy needs
of all subjects in the study, 6 variations of the ‘‘core diet’’ were
used to adjust energy intake by ±200 kcal of energy per day. Each
of the 6 variations of the ‘‘core diet’’ included the food vehicles.
Subjects with lower energy needs and micronutrient recom-
mended dietary allowances (RDA) received smaller portions of
the core diet that provided 1800–2000 kcal of energy per day. Sub-
jects with higher energy needs and micronutrient RDAs were given
larger portions of the core diet that provided 2400–3000 kcal of
energy per day. Using this approach, the intakes of nutrients of
interest were controlled, while providing essentially ad libitum
intake of energy.
In addition, subjects were weighed on a weekly basis to check
the need for adjustment of their dietary intake. Subjects were fed
to maintain enrollment weight (±5%) throughout the study. Sub-
jects were also asked to report feelings of hunger or excessive full-
ness during the study, and calories were adjusted based on this
subjective evaluation.
The (7-day rotating) menu provided approximately 35–40% of
calories from fat, 15% from protein, and 50% from carbohydrate.
The diets were formulated to ensure that the total digestible fat
content was comparable across the 4 study groups. The 35–40%
fat level was the lowest practically achievable because of the need
to supplement the EPG-containing diets with 10, 25, or 40 g/day of
regular triglyceride fats (e.g., margarine) to match the fat content of
the control diet. In other words, the triglycerides replaced by EPG
in mufﬁns, biscuits, cookies, and margarine were supplemented
by adding margarine in other parts of the diet. For example, com-
pared to the control group, the 10 g/day EPG study group con-
sumed 10 g/day less of ordinary triglyceride fat because it had
been replaced by the EPG in the select dietary food vehicles; there-
fore, an additional 10 g/day of triglycerides was added elsewhere
in the daily menu to keep the triglyceride levels equivalent to
the control group. The diets for the 25 and 40 g/day EPG study
groups were adjusted in the same manner.
The menu targeted between 80 and 120% of the RDA for vita-
mins A, D, and K, b-carotene, folate, zinc, and calcium. The levels
of vitamin B12, vitamin E, and phosphorus were consistent across
study groups. A vitamin D2 supplement (ergocalciferol, 400 IU)
was provided to each subject every morning.
In order to remain eligible, subjects were expected to consume
a minimum of 90% of the scheduled study meals. No more than six
consecutive study meals could have been missed at any given time
during the study without approval from the study director. Sub-
jects were not allowed to miss dinner on the day immediately prior
to blood/urine sampling.
Alcohol intake was discouraged and was documented by a die-
titian during daily interviews, along with consumption of any other
non-study food or drink. The portion size and nutrient value of any
such food or drink was assessed by the dietitian using the Minne-
sota Nutrition Data System, version 2.9.2.5. Measurement schedule
All subjects began the study on the same calendar day, except
for 31 subjects that began within 2 days thereafter. For the pur-
poses of limiting endogenous synthesis of vitamin D3, exposure
of subjects to sunlight was limited by conducting the study in Chi-
cago during the mid-late winter months.
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All blood and urine analyses were performed by Quest Diagnos-
tics (1355 Mittel Boulevard Wood Dale, IL), except for: vitamin D
analyses, which were performed by Dr. Bruce W. Hollis, Medical
University of South Carolina; and vitamin K analyses, which were
performed by Dr. John W. Suttie, University of Wisconsin.
2.7. Statistical analyses
2.7.1. Determination of sample size
Sample size and power calculations were based on the number
of subjects required to detect clinically important differences in
serum or plasma concentrations of b-carotene, retinol, a-tocoph-
erol (absolute and cholesterol-adjusted), and 25-OH vitamins D2
and D3. Based on the results of a prior fat substitute feeding study
conducted at the test facility, the standard deviations for changes
in these indicators of vitamin status were each expected to be
within the range of 12–20%. With at least 25 evaluable subjects
per group, the power (1-b) to detect a difference between groups
of one standard deviation (20% or less) was expected to be at least
85% at the 0.05 level of statistical signiﬁcance. Assuming an attri-
tion rate of less than 15%, a total sample size of 120 subjects (30
per treatment group) should have been sufﬁcient.
2.7.2. Criteria for data exclusion
Data from all subjects that entered the treatment portion of the
study were included in the analysis. Data from subjects that
dropped out before the treatment portion, i.e., before Day 1, were
excluded from analysis.
2.7.3. Demographic and baseline medical characteristics
Demographic variables were summarized and tested for treat-
ment group differences. Sex, race, and estimated energy needs
were tabulated by number (N) and percent, and tested using Pear-
son’s Chi-Square test. Continuous variables (age, height, weight,
body mass, and eating attitude score) were summarized by num-
ber, mean, standard deviation, minimum value, median value,
and maximum value, and tested using an analysis of variance
(ANOVA). Treatment was the only term in the model.
Baseline laboratory assessments for the primary outcome vari-
ables, as well as baseline vital sign (blood pressure, heart rate, res-
piration rate, and temperature) measurements were summarized
by number, mean, standard deviation, minimum value, median
value, and maximum value; and tested using an analysis of vari-
ance procedure. Treatment was the only term in the model.
Baseline physical and perianal examination measurements, and
baseline medical history were tabulated by treatment group.
2.7.4. Data sets analyzed
Two data sets were analyzed. The primary outcome analysis (i.e.,
target vitamin and nutrient status) included only the outcome
evaluable population, i.e., those study subjects that: (1) received
the study product at least once; (2) consumed a minimum of 90%
of the scheduled study meals; and (3) completed the Day 56
assessment. The intent-to-treat group consisted of all subjects that
gave consent to participate in the study, were randomized to a
treatment group, and consumed any of the study product; these
subjects were included in the analysis of changes from baseline
for b-carotene, retinol, a-tocopherol, 25-OH D2, 25-OH D3, phyllo-
quinone (K1), and PIVKA II.
The analysis based on the outcome evaluable population was
treated as the primary analysis; statistical signiﬁcance for this
analysis was declared at p 6 0.05. The safety analysis was con-
ducted on the intent-to-treat population only.For each of the outcome parameters, the number of subjects,
mean, median, standard deviation, and minimum and maximum
values are presented by treatment group and visit. The differences
between Day 56 and baseline values were calculated for each sub-
ject individually and reported using descriptive statistics: Number
of differences, mean difference, median difference, and standard
deviation for each of the four treatment groups. Ninety-ﬁve per-
cent conﬁdence intervals were also constructed for these differ-
ences. The ANOVA output was documented. The group-wise
concentration time proﬁles are depicted graphically.
Between Days 42 and 56 of the study, there was a change in the
standard used in the assay for blood vitamin levels, which required
application of a correction factor of (1.404) to the results
obtained during that period.
2.7.5. Primary endpoint analysis
The primary outcome endpoint was the comparison among the
four treatment groups with respect to change from baseline to end
of feeding period for serum b-carotene, retinol, a-tocopherol, 25-
OH D2, 25-OH D3, phylloquinone, and PIVKA-II. Baseline values
were deﬁned as the average of the non-missing pretreatment val-
ues obtained on Days 7 and 1. However, in the statistical anal-
yses presented on tables and listings, baseline is referred to as Day
1. End of feeding period values were deﬁned as the Day 56
measurement.
Dunnett’s test for multiple comparisons was used to compare
the mean change from baseline to Day 56 for each of the three
active treatment groups (EPG 10, EPG 25, EPG 40) vs. control. Sta-
tistical signiﬁcance was declared at the 0.05 level.
The primary outcome variables were summarized by age, body
mass, sex and race using descriptive statistics.
2.7.6. Secondary endpoint analysis
With the exception of serum concentrations of iron, calcium,
and phosphorus, all laboratory parameters were measured at Days
7, 1, 14, 28, 42, and 56. Serum concentrations of iron, calcium,
and phosphorus were measured at Days 42 to 15, 1, 14, 28,
42, and 56. The results are presented using 95% conﬁdence inter-
vals for change from baseline to Days 14, 28, and 42, as well as
for the comparison to control at each time point.
2.7.7. Nutrient intake
Nutrient intakes were determined from food consumption data
using the Minnesota Nutrition Data System, version 2.9. The data
were analyzed using daily averages over each of the four 2-week
periods, and over the entire 8-week study. The 95% conﬁdence
intervals for the mean differences between each of the three EPG
groups (10, 25, and 40 g/day) minus control were computed.
2.7.8. Safety and tolerability
Adverse events were summarized by body system. Further
summarization was performed for severity and relation to treat-
ment. The number and percent of subjects with at least one of
the 14 gastrointestinal adverse events (GI AEs) evaluated was tab-
ulated. The incidence of adverse events for each of the three EPG
treatment groups was compared to placebo by computing the dif-
ference in 95% conﬁdence intervals (CIs). Fisher’s exact test was
used to assess overall treatment effect for each of the individual
14 GI AEs. Tolerability data were also tabulated by age group
(18–29 and 30+), sex, race (white and non-white), body mass index
(low and high), and estimated caloric need (1800–2400 and 2600–
3000).
Other data (clinical laboratory test results, vital signs, physical
exam results, etc.) were classiﬁed as normal or abnormal, and pre-
sented using descriptive statistics.
S146 M.H. Davidson, D.H. Bechtel / Regulatory Toxicology and Pharmacology 70 (2014) S143–S1573. Results
3.1. Disposition and evaluability of subjects
The overall disposition of subjects is summarized in Table 1. A
total of 139 subjects were enrolled (consumed study product);
107 (77%) completed the study. The percentage of subjects that
consumed study product and that completed the study was com-
parable among groups. Across groups, the number of subjects that
withdrew from the study ranged from 6 (17.6%) subjects in the EPG
10 group to 9 subjects in each the EPG 25 (25.7%) and control
(25.0%) groups. The two primary reasons for premature termina-
tion from the study were non-compliance and adverse event occur-
rence. Overall, 28 (20.1%) subjects were terminated for
noncompliance. Four (2.9%) subjects were terminated due to
adverse events; one subject each from the control and EPG 10
groups, and two from the EPG 25 group. No statistically signiﬁcant
differences were detected across groups in the number of subjects
that complied with the 90% consumption of study meals
requirement.
Two subjects from the placebo group and one subject from the
EPG 25 became pregnant during the study; these subjects were not
using oral contraceptives. All three of the subjects were terminated
from the study, having received the last study meal between study
Days 15 and 30.3.2. Demographics
Demographic characteristics of the subjects evaluable for the
outcome analysis are provided in Table 2. No signiﬁcant differences
in demographic and baseline characteristics were noted; these
parameters were similar to the all-subject population.3.3. Primary outcome
Tables 3–9 summarize the changes in mean circulating b-caro-
tene, retinol, a-tocopherol, 25-OH D2, 25-OH D3, phylloquinone,Table 1
Overall subject disposition.
Control EPG (g/day)
10
Consumed study product 36 (100%) 34 (100%)
Prematurely terminated 9 (25%) 6 (17.6%)
Primary reason
Adverse eventa 1 (2.8%) 1 (2.9%)
Non-compliance 8 (22.2%) 5 (14.7%)
Missed study meals 3 (8.3%) 2 (5.9%)
Withdrew consent 2 (5.6%) 2 (5.9%)
Out of town 1 (2.8%) 0
Scheduling conﬂict 0 1 (2.9%)
Pregnancy 2 (5.6%) 0
Completed study 27 (75%) 28 (82.4%)
Evaluable for outcome analysis?
Yes 27 (75%) 27 (79.4%)
No 9 (25%) 7 (20.6%)
a Adverse events leading to discontinuation were as follows:Subject # 508, a 37-yea
moderate to severe constipation from Days 6 to 27, along with mild to moderate passin
judged by the investigator to be possibly related to the study meals. The subject’s constip
last study meal was on Day 30.
Subject # 142, a 22-year-old female receiving EPG 10 g/day, experienced moderate and m
possibly related to the test substance. The nausea was treated with antacids (Tums, 2 ta
Subject # 106, a 22-year-old female, receiving EPG 25 g/day, experienced severe abdomin
history of constipation over about 5 years. The investigator judged the abdominal bloatin
judged to be unrelated. No therapy was required. The last study meal was on Day 6.
Subject # 148, a 21-year-old female receiving EPG 25 g/day, experienced moderate oily ur
the investigator to be possibly related to the test substance. The headache was judged tand PIVKA-II from baseline to the end of the study, respectively
(subjects evaluable for outcome analysis); Figs. 1–7 show the
means over time (intent-to-treat population).
3.3.1. b-Carotene
Mean circulating b-carotene levels declined over time in all sub-
jects, including the control group (Fig. 1). As Table 3 illustrates,
based on the calculated 95% conﬁdence intervals (CIs), the
within-group changes from baseline were statistically signiﬁcant
in all groups and all time points, with two exceptions: the
increases from baseline by 3.5 and 0.1 lg/dL in the control group
at Days 14 and 42. In addition, compared to the changes seen in
the control group, the declines from baseline levels among subjects
receiving EPG were signiﬁcantly greater (p value of less than the
adjusted 0.05  3 = 0.017) at all time points. However, there was
no apparent relationship to EPG concentration, since the declines
were consistently greater in the groups receiving 10 g/day and
40 g/day than in the 25 g/day group.
3.3.2. Retinol (vitamin A)
Despite declining from baseline to Day 14 across all groups,
mean retinol levels increased steadily from Day 14 to Day 56 to
levels approaching or surpassing baseline values (Fig. 2). Within
groups, the changes from baseline were statistically signiﬁcant
only for EPG 10 at Days 42 and 56, and at endpoint (increases of
5.2, 6.7, and 6.7 lg/dL, respectively), and for EPG 25 at Days 14
and 28 (decreases of 8.4 and 6.4 lg/dL, respectively). There was
no apparent relationship to EPG concentration. Overall, the
changes from baseline retinol levels were not signiﬁcantly differ-
ent between the control and EPG groups, except for EPG 25 which
exhibited a decline from baseline to Day 14 that was signiﬁcantly
(p = 0.0141) greater than the baseline to Day 14 change in the con-
trol (Table 4).
3.3.3. a-Tocopherol (vitamin E)
All groups had an initial decrease from baseline in mean circu-
lating a-tocopherol levels (Fig. 3), followed by a gradual increase,Total
25 40
35 (100%) 34 (100%) 139 (100%)
9 (25.7%) 8 (23.5%) 32 (23%)
2 (5.7%) 0 4 (2.9%)
7 (20%) 8 (23.5%) 28 (20.1%)
2 (5.7%) 4 (11.8%) 11 (7.9%)
1 (2.9%) 2 (5.9%) 7 (5%)
2 (5.7%) 1 (2.9%) 4 (2.9%)
1 (2.9%) 1 (2.9%) 3 (2.2%)
1 (2.9%) 0 3 (2.2%)
26 (74.3%) 26 (76.5%) 107 (77%)
24 (68.6%) 25 (73.5%) 103 (74.1%)
11 (31.4%) 9 (26.5%) 36 (25.9%)
r-old female from the control group (normal triglycerides) experienced recurring
g gas (Days 11 and 20), and moderate diarrhea (Day 11). All adverse events were
ation was treated with herbal and vegetable laxatives (Metamucil and Colace). The
ild nausea on Days 2 and 4, respectively. The investigator judged both episodes to be
blets per day). The last study meal was on Day 6.
al bloating and cramping, diarrhea, and fatigue on Day 7; the subject had reported a
g, cramping, and diarrhea as possibly related to the test substance. The fatigue was
ine and stools, and mild headache on Day 5. The oily urine and stools were judged by
o be unrelated. No therapy was required. The last study meal was on Day 6.
Table 2
Demographics of subjects evaluable for outcome analysis.
Control EPG(g/day) Total p-Value
10 25 40
Sex
Male 12 (44.4%) 9 (33.3%) 9 (37.5%) 8 (32%) 38 (36.9%) 0.7845
Female 15 (55.6%) 18 (66.7%) 15 (62.5%) 17 (68%) 65 (63.1%)
Race
Asian 2 (7.4%) 5 (18.5%) 6 (25%) 5 (20%) 18 (17.5%) 0.5769
Caucasian 6 (22.2%) 7 (25.9%) 7 (29.2%) 3 (12%) 23 (22.3%)
Black 16 (59.3%) 10 (37%) 10 (41.7%) 14 (56%) 50 (48.5%)
Hispanic 3 (11.1%) 4 (14.8%) 1 (4.2%) 3 (12%) 11 (10.7%)
Other 0 1 (3.7%) 0 0 1 (1%)
Age (years)
N 27 27 24 25 103 0.3761
Mean (SD) 30.1 (8.4) 30.3 (9.1) 30.7 (8.8) 27 (7.4) 29.5 (8.5)
Median 29 28 28 24 28
Min–max 18–47 19–48 20–48 18–42 18–48
Weight (lbs)
N 25 27 24 24 100 0.6216
Mean (SD) 153.6 (22.6) 159 (28.6) 157.7 (33.4) 148.3 (38.1) 154.8 (30.9)
Median 155.5 156 155 138 153.5
Min–max 105–210 109–213 110–245 100–234 100–245
Height (in)
N 26 27 24 24 101 0.9220
Mean (SD) 65.7 (3.5) 65.6 (2.5) 66 (3.6) 65.3 (3.3) 65.7 (3.2)
Median 66 66 66 65.3 66
Min–max 59.8–72.5 59.3–70.3 58.5–73 58.8–73 58.5–73
Body mass index
N 25 27 24 24 100 0.5200
Mean (SD) 25.1 (3.5) 25.9 (4) 25.4 (4.6) 24.2 (4.6) 25.2 (4.2)
Median 25.2 25.3 25.5 23.4 25
Min–max 19.7–32.6 19–32.7 18.4–32.7 17.7–34.1 17.7–34.1
Eating attitude surveya score
N 27 27 24 25 103 0.7741
Mean (SD) 9 (8.2) 8.3 (4.6) 8.2 (4.4) 7.4 (4.7) 8.2 (5.7)
Median 7 7 8 6 7
Min–max 2–41 1–20 2–22 1–22 1–41
Estimated energy needs
1800–2400 23 (85.2%) 23 (85.2%) 21 (87.5%) 21 (84%) 88 (85.4%) 0.9885
2600–3000 4 (14.8%) 4 (14.8%) 3 (12.5%) 4 (16%) 15 (14.6%)
a Subjects were required to have a score of less than 30 points in the eating attitude survey to qualify for participation in the study.
Control
EPG 10
EPG 25
EPG 40
0
5
10
15
20
25
30
35
40
g/
dL
m
Baseline Day 14 Day 28 Day 42 Day 56
Fig. 1. Circulating b-carotene levels over time. Values represent mean ± standard deviation (SD).
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levels. However, the decline was greater and more persistent
for the EPG 25 and EPG 40 groups. Based on 95% CIs (Table 5),
EPG 25 and EPG 40 showed signiﬁcantly greater declines at
Day 14 (1.9 and 1.7 mg/L, respectively), Day 28 (1.4 and
0.9 mg/L), and Day 42 (1 and 0.3 mg/L). There were no sta-
tistically signiﬁcant declines in a-tocopherol at Day 56 for any
of the EPG groups.3.3.4. 25-OH D2 (vitamin D, ergocalciferol)
As Fig. 4 shows, all study groups had a gradual increase in mean
circulating 25-OH D2 levels from baseline until Day 42, with a
slight attenuation at Day 56. The increases were statistically signif-
icant from Day 28 onward in all groups, except for the EPG 25
group, which had an increase that was only slightly greater at
Day 28 than it was at Day 14 (1.4 vs. 1.2 ng/mL). The Wilcoxon
Rank Sum Test (Table 6) revealed no signiﬁcant differences at the
Table 3
Summary statistics for changes from baseline in blood b-carotene (l/dL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 22 3.5 12.1 [1.6, 8.5]
EPG 10 22 10.3 8.1 [13.6, 6.9] 13.7 [19.8, 7.6] 0.0001
EPG 25 19 7.7 11.4 [12.8, 2.5] 11.1 [18.4, 3.9] 0.0002
EPG 40 16 17.6 27.3 [30.9, 4.2] 21.0 [33.8, 8.2] 0.0001
Day 28
Control 26 5.9 8.1 [2.8, 9.0]
EPG 10 26 10.4 11.6 [14.9, 6.0] 16.3 [21.8, 10.9] 0.0001
EPG 25 24 9.0 12.9 [14.2, 3.9] 14.9 [20.8, 9.0] 0.0001
EPG 40 24 16.7 37.6 [31.8, 1.7] 22.7 [37.5, 7.8] 0.0001
Day 42
Control 25 0.1 6.3 [2.4, 2.6]
EPG 10 26 16.6 14.3 [22.1, 11.1] 16.7 [22.8, 10.6] 0.0001
EPG 25 24 11.4 13.0 [16.6, 6.2] 11.5 [17.1, 5.8] 0.0001
EPG 40 24 14.0 17.0 [20.8, 7.2] 14.1 [21.2, 7.0] 0.0001
Day 56
Control 25 4.6 5.0 [6.6, 2.7]
EPG 10 27 20.6 14.2 [26.0, 15.3] 16.0 [21.9, 10.1] 0.0001
EPG 25 24 14.7 13.4 [20.0, 9.3] 10.1 [15.7, 4.4] 0.0001
EPG 40 23 24.1 37.0 [39.2, 9.0] 19.5 [34.1, 4.9] 0.0001
Endpoint***
Control 26 4.4 5.1 [6.4, 2.5]
EPG 10 27 20.6 14.2 [26.0, 15.3] 16.2 [22.0, 10.4] 0.0001
EPG 25 24 14.7 13.4 [20.0, 9.3] 10.3 [15.8, 4.8] 0.0001
EPG 40 25 23.1 35.6 [37.1, 9.2] 18.7 [32.5, 4.9] 0.0001
* 95% conﬁdence intervals were used to compare the change from baseline to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
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Fig. 2. Circulating retinol (vitamin A) levels over time. Values represent mean ± standard deviation (SD).
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OH D2 levels in EPG vs. control subjects; similar results were
obtained at Days 14, 28, and 42, and at the endpoint analysis.3.3.5. 25-OH D3 (vitamin D, cholecalciferol)
As Fig. 5 illustrates, in the control group, mean 25-OH D3 levels
rose over time to levels that far exceeded baseline levels, reaching
a maximum on Day 42 and declining thereafter, but remaining
higher than baseline. In general, circulating 25-OH D3 levels also
increased over time in the EPG groups, but to a lesser extent and
at a slower pace. At the end of the study (Day 56), only EPG 25
and EPG 40 had 25-OH D3 levels below baseline levels (1.7 and
1.3 ng/mL, respectively, Table 7). The within-group differences
from baseline were not statistically signiﬁcant for any group,
except for the control group (increases at all time points). Com-bined with only gradually rising levels in the EPG groups, this
resulted in the differences from baseline in the EPG groups appear-
ing to be mostly statistically signiﬁcant declines (see Table 7, neg-
ative differences vs. control). In actuality, after the initial (Day 14)
decline seen in all EPG groups, 25-OH D3 levels were consistently
higher than baseline in the EPG 10 group through the end of the
study; levels were reduced only for the EPG 25 (after Day 42)
and EPG 40 (Day 56 and endpoint) groups.3.3.6. Phylloquinone (vitamin K1)
Mean circulating phylloquinone levels were consistently
higher among control subjects at all time points, including base-
line (Fig. 6). With the exception of EPG 40, values declined ini-
tially among all groups from baseline to Day 14, increased until
Day 42, and showed a slight attenuation by Day 56. In the control
Table 4
Summary statistics for changes from baseline in blood retinol (vitamin A) (lg/dL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 18 1.5 5.2 [3.9, 0.9] 0.59 [5.1, 6.3] 0.5741
EPG 10 17 0.9 11.1 [6.2, 4.3] 6.87 [12.3, 1.5] 0.0141
EPG 25 14 8.4 10.1 [13.7, 3.1] 5.78 [12.6, 1.0] 0.2290
EPG 40 13 7.3 13.4 [14.6, 0]
Day 28
Control 23 2.5 6.6 [5.1, 0.2]
EPG 10 23 1.0 7.8 [2.2, 4.2] 3.46 [0.7, 7.6] 0.1794
EPG 25 19 6.4 10.4 [11.1, 1.8] 3.99 [9.2, 1.2] 0.0827
EPG 40 22 2.7 10.9 [7.2, 1.9] 0.23 [5.5, 5.0] 0.3453
Day 42
Control 22 2.6 8.3 [0.8, 6.1]
EPG 10 22 5.2 7.9 [1.9, 8.5] 2.57 [2.2, 7.4] 0.4236
EPG 25 19 2.2 9.6 [6.6, 2.1] 4.85 [10.3, 0.6] 0.0648
EPG 40 22 0.9 12.8 [4.5, 6.3] 1.70 [8.1, 4.7] 0.4808
Day 56
Control 22 4.7 10.7 [0.2, 9.1]
EPG 10 23 6.7 7.3 [3.7, 9.7] 2.04 [3.3, 7.4] 0.3692
EPG 25 19 1.2 11.4 [3.9, 6.4] 3.42 [10.2, 3.4] 0.5043
EPG 40 21 3.5 12.5 [1.8, 8.9] 1.14 [8.1, 5.8] 0.7704
Endpoint***
Control 23 4.1 10.9 [0.4, 8.5]
EPG 10 23 6.7 7.3 [3.7, 9.7] 2.63 [2.7, 8.0] 0.2620
EPG 25 19 1.2 11.4 [3.9, 6.4] 2.83 [9.6, 3.9] 0.6487
EPG 40 22 3.7 12.2 [1.4, 8.8] 0.34 [7.1, 6.4] 0.9909
* 95% conﬁdence intervals were used to compare the change from baseline to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
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Fig. 3. Circulating a-tocopherol (vitamin E) levels over time. Values represent mean ± standard deviation (SD).
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Day 14, whereas the EPG groups had levels below baseline at
all time points after Day 14. In the EPG 40 group, phylloquinone
levels ﬂuctuated between decreasing and increasing. Calculated
95% conﬁdence intervals for within-group differences showed
no trend in statistical signiﬁcance. A comparison of the differ-
ences from baseline in EPG groups vs. control showed statistical
signiﬁcance (decline in phylloquinone levels) in nearly all EPG
groups at nearly all time points. However, the declines did not
exceed 0.1 ng/mL (Table 8).
3.3.7. PIVKA-II (proteins induced in vitamin K absence)
PIVKA-II was inadvertently dropped from the laboratory requisi-
tion format various timepoints. Consequently, PIVKA-II valueswereavailable only for the baseline and Day 56 time points. Calculated
95% conﬁdence intervals showed concentration-dependent
increases from baseline PIVKA-II levels among EPG groups, reaching
statistical signiﬁcance only for the EPG 25 and EPG 40 groups
(Table 9). Compared to control group, the changes from baseline in
the EPG 25 and EPG 40 groups were also statistically signiﬁcant
(p 6 0.017).
Subgroup analyses based on sex, race (black and non-black), age
(18–29, and 30+), and body mass index (625 and >25) revealed no
notable differences for any of theprimary outcomemeasures (retinol,
a-tocopherol, 25-OH D2, 25-OH D3, phylloquinone, PIVKA-II), except
b-carotene. EPGwas associated with slightly greater decline inmean
b-carotene levels among females (all dose levels) and among EPG 10
andEPG40subjectswitha smaller bodymass index (datanot shown).
Table 5
Summary statistics for changes from baseline in blood a-tocopherol (vitamin E) (mg/L).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 22 0.5 1.2 [1.0, 0]
EPG 10 21 1.0 1.9 [1.8, 0.2] 0.44 [1.4, 0.5] 0.3430
EPG 25 19 1.9 2.5 [3.0, 0.7] 1.33 [2.5, 0.2] 0.0498
EPG 40 16 1.7 2.0 [2.6, 0.7] 1.12 [2.1, 0.1] 0.0166
Day 28
Control 27 0.1 1.0 [0.3, 0.4]
EPG 10 26 0.7 1.7 [1.4, 0.1] 0.79 [1.5, 0] 0.0616
EPG 25 24 1.4 2.0 [2.2, 0.6] 1.44 [2.3, 0.6] 0.0014
EPG 40 25 0.9 1.5 [1.4, 0.3] 0.90 [1.6, 0.2] 0.0152
Day 42
Control 26 0.8 1.1 [0.4, 1.3]
EPG 10 26 0.1 2.2 [0.9, 0.8] 0.92 [1.9, 0] 0.1241
EPG 25 24 1.0 1.8 [1.7, 0.3] 1.86 [2.7, 1.0] 0.0001
EPG 40 25 0.3 1.8 [1.1, 0.4] 1.19 [2.0, 0.4] 0.0017
Day 56
Control 26 1.3 1.1 [0.8, 1.7]
EPG 10 27 0.8 1.8 [0.1, 1.4] 0.48 [1.3, 0.3] 0.4337
EPG 25 24 0.3 2.2 [0.6, 1.2] 0.96 [1.9, 0] 0.2140
EPG 40 23 0.6 1.8 [0.2, 1.3] 0.68 [1.5, 0.2] 0.0624
Endpoint***
Control 27 1.2 1.1 [0.8, 1.6]
EPG 10 27 0.8 1.8 [0.1, 1.4] 0.45 [1.2, 0.3] 0.4835
EPG 25 24 0.3 2.2 [0.6, 1.2] 0.93 [1.9, 0] 0.2655
EPG 40 25 0.5 1.8 [0.2, 1.2] 0.71 [1.5, 0.1] 0.0490
A correction factor of 1.404 was used for samples analyzed on Day 56.
* Assuming normal approximation.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
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Fig. 4. Circulating 25-OH D2 (ergocalciferol) levels over time. Values represent mean ± standard deviation (SD).
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As Tables 10–12 show, there were no statistically signiﬁcant dif-
ferences (EPG vs. control) at any time point in themean change from
baseline in serum folate, vitamin B12, zinc, iron, calcium, phospho-
rus, intact PTH, PT, PTT, RBP, osteocalcin, undercarboxylated osteo-
calcin, cholesterol, and triglycerides. The more limited (Day 28)
data onRBC folate,HDL-C, and LDL-C showed statistically signiﬁcant
changes (declines) only for LDL-C in the EPG 25 and EPG 40 groups.3.4.1. Overall safety and tolerability
Mean body weight values remained constant throughout the
study; the majority of subjects having less than a 5% change from
baseline weight (data not shown).Some deviations from normal values were observed in mean
hematology, serum chemistry, and urinalysis parameters during
the study (data not shown). However, none of the deviations was
considered clinically signiﬁcant, having already been present at
baseline and/or not resulting in any adverse effect. The results of
24-h urine sample analysis for zinc, sodium, potassium, calcium,
creatinine, and phosphorus showed no evidence of any treat-
ment-related effects (data not shown).
Physical examination at the end of the study, including vital
signs, review of general body systems, and inspection of the peria-
nal area, revealed no clinically-signiﬁcant changes. The majority of
subjects did not have any signiﬁcant changes in health or medica-
tions during the study period.
As previously noted, three subjects were prematurely termi-
nated from the study due to pregnancy. No complications with
Table 6
Summary statistics for changes from baseline in blood 25-OH D2 (ergocalciferol) (ng/mL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 27 0.8 2.1 [0, 1.6]
EPG 10 27 0.6 2.0 [0.2, 1.3] 0.26 [1.4, 0.8] 0.8220
EPG 25 23 1.2 2.3 [0.3, 2.2] 0.41 [0.8, 1.6] 0.5080
EPG 40 25 0.7 1.7 [0, 1.3] 0.16 [1.2, 0.9] 0.8980
Day 28
Control 27 1.7 2.0 [0.9, 2.4]
EPG 10 27 1.0 2.1 [0.2, 1.8] 0.72 [1.8, 0.4] 0.2795
EPG 25 23 1.4 3.5 [0, 2.8] 0.28 [1.8, 1.3] 0.3501
EPG 40 25 2.3 4.2 [0.6, 3.9] 0.62 [1.2, 2.4] 0.5335
Day 42
Control 25 2.0 2.3 [1.1, 3.0]
EPG 10 27 1.9 3.3 [0.7, 3.2] 0.11 [1.7, 1.4] 0.5274
EPG 25 24 2.9 6.4 [0.4, 5.5] 0.88 [1.8, 3.5] 0.9601
EPG 40 25 2.6 3.6 [1.2, 4.0] 0.56 [1.1, 2.2] 0.7342
Day 56
Control 27 1.7 1.9 [0.9, 2.4]
EPG 10 27 0.9 2.2 [0.1, 1.7] 0.79 [1.9, 0.3] 0.2004
EPG 25 23 1.5 2.0 [0.7,2.3] 0.17 [1.3, 0.9] 0.5206
EPG 40 24 1.6 2.9 [0.4, 2.8] 0.07 [1.4, 1.3] 0.3956
Endpoint***
Control 27 1.7 1.9 [0.9, 2.4]
EPG 10 27 0.9 2.2 [0.1, 1.7] 0.79 [1.9, 0.3] 0.2004
EPG 25 24 2.8 6.4 [0.2, 5.3] 1.09 [1.5, 3.6] 0.7128
EPG 40 25 1.5 2.9 [0.4, 2.7] 0.15 [1.5, 1.2] 0.3181
* Assuming normal approximation.
** Wilcoxon Rank Sum Test was used to compare the three EPG treatment groups vs. placebo.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
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Fig. 5. Circulating 25-OH D3 (cholecalciferol) levels over time. Values represent mean ± standard deviation (SD).
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ever, further attempts to follow-up with the subjects were
unsuccessful.
No serious adverse events were reported during this study, and
only 4 (2.9%) subjects were terminated for adverse events (see
Table 1). All adverse events reported by subjects in this study are
summarized in Table 13. In general, with the exception of gastro-
intestinal tract symptoms, adverse events were not considered
related to EPG.
Seven of the 14 pre-deﬁned Gl AEs were reported with signiﬁ-
cantly (p 6 0.05) greater frequency by subjects receiving 25 or
40 g/day of EPG: gas with discharge; diarrhea; oily spotting; oily
evacuation; oily stool; liquid stool; and soft stool. In general, the
frequency of GI AEs appeared to be directly related to EPG dietary
concentration. However, with the exception of oily stool, there
were no statistically signiﬁcant differences between the EPG 10
group and the control group.Post-hoc analyses revealed an overall increase in the mean per-
cent days with any GI AE (days with any GI AE/days on trial  100)
with increasing EPG concentration (data not shown). The mean
percent of days with any GI AE was 5.6 days in the control group,
compared with 11, 12.7, and 15.9 in the EPG 10, EPG 25, and EPG
40 groups, respectively.
Post-hoc analysis for the number of subjects experiencing
moderate to severe GI AEs showed statistical signiﬁcance in the
EPG vs. control groups for: gas with discharge (p = 0.0043); oily
spotting (p = 0.0072); oily stool (p = 0.0012); and soft stool
(p = 0.0002).
The most commonly reported GI AE, lasting for at least two suc-
cessive days, was passing gas, with 3 (11.1%), 4 (14.8%), 4 (16.7%),
and 5 (20%) subjects in each the control, EPG 10, EPG 25, and EPG
40 groups, respectively. For the control group, the number of sub-
jects reporting GI AEs lasting at least two successive days was less
than 5%, except for abdominal bloating/cramping, which was
Table 7
Summary statistics for changes from baseline in blood 25-OH D3 (cholecalciferol) (ng/mL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 27 1.4 3.2 [0.2, 2.6]
EPG 10 27 0.2 3.7 [1.6, 1.2] 1.55 [3.4, 0.3] 0.0582
EPG 25 23 0.9 2.3 [1.9, 0] 2.29 [3.9, 0.7] 0.0040
EPG 40 25 0.2 1.8 [0.9, 0.5] 1.59 [3.0, 0.2] 0.0243
Day 28
Control 27 3.9 3.5 [2.6, 5.2]
EPG 10 27 0.9 2.9 [0.2, 2.0] 2.98 [4.7, 1.3] 0.0013
EPG 25 23 0.2 3.2 [1.2, 1.5] 3.75 [5.6, 1.9] 0.0004
EPG 40 25 0.4 2.5 [0.5, 1.4] 3.48 [5.1, 1.8] 0.0001
Day 42
Control 25 4.4 5.1 [2.4, 6.4]
EPG 10 27 0.8 3.3 [0.4, 2.1] 3.61 [5.9, 1.3] 0.0033
EPG 25 24 0.1 3.9 [1.6, 1.5] 4.48 [7.0, 1.9] 0.0008
EPG 40 25 0.6 2.4 [0.3, 1.6] 3.80 [6.0, 1.6] 0.0012
Day 56
Control 27 2.6 5.4 [0.5, 4.6]
EPG 10 27 0.1 3.9 [1.3, 1.6] 2.44 [5.0, 0.1] 0.0127
EPG 25 23 1.7 5.0 [3.7, 0.4] 4.25 [7.2, 1.3] 0.0020
EPG 40 24 1.3 4.0 [2.9, 0.3] 3.83 [6.5, 1.2] 0.0017
Endpoint***
Control 27 2.6 5.4 [0.5, 4.6]
EPG 10 27 0.1 3.9 [1.3, 1.6] 2.44 [5.0, 0.1] 0.0127
EPG 25 24 1.6 4.9 [3.5, 0.4] 4.14 [7.0, 1.3] 0.0019
EPG 40 25 1.1 4.0 [2.7, 0.5] 3.66 [6.3, 1.0] 0.0020
* 95% conﬁdence intervals were used to compare the change from baseline to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
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Fig. 6. Circulating phylloquinone (vitamin K1) levels over time. Values represent mean ± standard deviation (SD).
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Fig. 7. Circulating PIVKA-II (proteins induced in vitamin K absence) levels at baseline and end of study. Values represent mean ± standard deviation (SD).
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Table 8
Summary statistics for changes from baseline in blood phylloquinone (vitamin K1) (ng/mL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 14
Control 24 0 0.2 [0.1, 0.1]
EPG 10 25 0.1 0.2 [0.2, 0] 0.09 [0.2, 0] 0.0054
EPG 25 21 0.1 0.2 [0.2, 0] 0.08 [0.2, 0] 0.0098
EPG 40 21 0 0.3 [0.2, 0.1] 0.01 [0.2, 0.1] 0.0140
Day 28
Control 24 0.1 0.2 [0, 0.2]
EPG 10 24 0.1 0.1 [0.1, 0] 0.12 [0.2, 0] 0.0024
EPG 25 20 0.1 0.2 [0.2, 0] 0.15 [0.3, 0] 0.0014
EPG 40 19 0.1 0.1 [0.1, 0.1] 0.17 [0.3, 0.1] 0.0001
Day 42
Control 20 0.1 0.2 [0.1, 0.2]
EPG 10 25 0 0.2 [0.1, 0.1] 0.16 [0.3, 0.1] 0.0009
EPG 25 21 0.1 0.2 [0.2, 0] 0.22 [0.3, 0.1] 0.0001
EPG 40 18 0.1 0.1 [0.1, 0] 0.22 [0.3, 0.1] 0.0001
Day 56
Control 23 0 0.2 [0.1, 0.1]
EPG 10 26 0.1 0.2 [0.1, 0] 0.11 [0.2, 0] 0.0242
EPG 25 22 0.1 0.2 [0.2, 0] 0.12 [0.3, 0] 0.0087
EPG 40 22 0.1 0.1 [0.1, 0.1] 0.13 [0.2, 0] 0.0027
Endpoint***
Control 25 0 0.3 [0.1, 0.1]
EPG 10 27 0.1 0.2 [0.1, 0] 0.12 [0.2, 0] 0.0200
EPG 25 23 0.1 0.2 [0.2, 0] 0.12 [0.3, 0] 0.0093
EPG 40 22 0.1 0.1 [0.1, 0.1] 0.14 [0.2, 0] 0.0029
* 95% conﬁdence intervals were used to compare the change from baseline to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
*** Subjects with data on or after Day 14 were included in the endpoint analysis, using the last observation carried forward (LOCF).
Table 9
Summary statistics for changes from baseline in blood PIVKA-II (proteins induced in vitamin K absence) (U/mL).
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Day 56
Control 24 0.1 2.4 [0.9, 1.0]
EPG 10 25 0.4 1.7 [0.2, 1.1] 0.36 [0.8, 1.5] 0.0702
EPG 25 22 1.7 3.3 [0.3, 3.1] 1.68 [0, 3.3] 0.0032
EPG 40 19 1.9 3.6 [0.3, 3.5] 1.85 [0, 3.7] 0.0049
* 95% conﬁdence intervals were used to compare the change from baseline to Day 56 and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
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least two successive days were reported by less than 10% of sub-
jects, except for abdominal bloating/cramping in 4 (14.8%) sub-
jects; constipation in 4 (14.8%) subjects; and urgency of bowel
movement in 3 (11.1%) subjects. In the EPG 25 group, 3 (12.5%)
subjects reported each of the following events: gas with discharge,
oily evacuation, oily stool, and soft stool for two or more successive
days. All other GI-related events in this group were reported by
less than 10% of subjects. GI AEs lasting more than two successive
days were reported by less than 10% of subjects from the EPG 40
group, except for abdominal bloating/cramping in 4 (16%) subjects,
urgency of bowel movement in 3 (12%) subjects, and soft stool in 3
(12%) subjects.
Subgroup analyses based on sex, race (black and non-black), age
(18–29, and 30+), and body mass index (625 and >25) revealed
that females consistently reported more GI AEs than males. No
other statistically signiﬁcant differences were noted among the
subgroups.3.4.2. Nutrient Intake
Nutrient intakes were determined from food consumption data
after the study was completed, over 17 years ago. There are, how-
ever, some apparent inconsistencies in the nutrient intake results
that cannot be resolved, because detailed food consumption
records are no longer available. Speciﬁcally, the mean daily intakes
of selenium and vitamin D appear on record to have been signiﬁ-
cantly greater (based on 95% CIs) among subjects receiving EPG
(vs. control) at all time points, in a concentration-dependent man-
ner. For vitamin D, intakes were approximately 1.1, 1.4, and 1.6
times as high as the control in each the EPG 10, EPG 25, and EPG
40 groups, respectively; for selenium intakes were approximately
1.1, 1.3, and 1.4 times greater. The source of the additional
amounts of these nutrients in the EPG groups is uncertain,
although it might have been due to human error when entering
the data into the nutrient database.
Each of the six variations of the diet administered to subjects in
this study included the food vehicles (spread, mufﬁns, cookies, bis-
Table 10
Mean change from baseline to the end of the study in blood folate, vitamin B12, zinc, iron, calcium, and phosphorus.
N Change SD 95% CI* Comparison to control
Difference 95% Cl p-Value**
Folate (lg/L)
Control 25 2.2 3.5 [0.9, 3.6]
EPG 10 22 1.8 4.3 [0, 3.6] 0.44 [2.7, 1.8] 0.9405
EPG 25 21 1.5 5.4 [0.8, 3.8] 0.75 [3.3, 1.8] 0.6119
EPG 40 22 2.0 3.7 [0.5, 3.5] 0.25 [2.3, 1.8] 0.6088
RBC folatea (lg/dL)
Control 25 41.1 59.5 [17.8, 64.5]
EPG 10 27 42.6 46.0 [25.2, 59.9] 1.45 [27.3, 30.2] 0.8260
EPG 25 24 23.3 64.0 [2.3, 48.9] 17.8 [52.4, 16.7] 0.4237
EPG 40 24 39.8 43.9 [22.2, 57.3] 1.39 [30.8, 28.0] 0.8103
Vitamin B12 (pg/mL)
Control 25 23.0 122 [24.7, 70.6]
EPG 10 22 39.1 127 [92.4, 14.1] 62.1 [133.0, 9.1] 0.2496
EPG 25 21 28.7 75.1 [60.8, 3.4] 51.7 [111.0, 8.1] 0.2048
EPG 40 22 31.8 83.1 [66.5, 3.0] 54.7 [115.0, 5.7] 0.2864
Zinc (lg/dL)
Control 27 12.3 16.4 [18.5, 6.1]
EPG 10 27 13.2 12.2 [17.8, 8.6] 0.96 [8.7, 6.7] 0.7162
EPG25 24 9.5 13.0 [14.7, 4.3] 2.82 [5.4, 11.0] 0.5457
EPG40 24 11.7 17.1 [18.6, 4.9] 0.57 [8.6, 9.8] 0.8134
Iron (lg/dL)
Control 26 0.2 36.1 [13.7, 14.1]
EPG 10 27 4.8 34.3 [17.7, 8.1] 4.99 [24.0, 14.0] 0.7152
EPG 25 24 8.8 43.3 [8.6, 26.1] 8.56 [13.5, 30.6] 0.2479
EPG 40 24 1.6 37.3 [13.3, 16.5] 1.41 [19.0, 21.8] 0.9072
Calcium (mg/dL)
Control 26 0.2 0.5 [0, 0.4]
EPG 10 27 0 0.3 [0.1, 0.1] 0.15 [0.4, 0.1] 0.3308
EPG25 24 0 0.5 [0.2, 0.2] 0.17 [0.4, 0.1] 0.2800
EPG 40 24 0 0.4 [0.2, 0.1] 0.18 [0.5, 0.1] 0.2385
Phosphorus (mg/dL)
Control 26 0.1 0.4 [0, 0.3]
EPG 10 27 0.2 0.3 [0.1, 0.3] 0.11 [0.1, 0.3] 0.3396
EPG25 24 0.1 0.5 [0.1, 0.3] 0.01 [0.3, 0.3] 0.9302
EPG40 24 0.3 0.7 [0, 0.6] 0.16 [0.2, 0.5] 0.2473
Data shown for subjects evaluable for outcome analysis (see Section 2).
a Data for RBC folate only available through Day 28.
* 95% conﬁdence intervals were used to compare the change from baseline (Day-1) to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
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taining either EPG or margarine (i.e., double-blind study design),
the person(s) entering the data into the system would have needed
additional information, such as a nutritional information label or a
list of ingredients with amounts (ﬂour, sugar, etc.) for each of the
target foods; the former providing a more reliable measure of
nutrient intake than the latter. If the EPG ‘‘spread’’ was erroneously
classiﬁed as ‘‘margarine’’, for example, this might have resulted in
miscalculated nutrient (e.g., vitamin D) intakes.
Analysis of the existing nutrient intake data (95% CIs) otherwise
showed no statistically signiﬁcant differences between EPG groups
and the control group for the average daily intake of calcium, cho-
lesterol, dietary ﬁber, total energy, folacin, water-soluble and insol-
uble dietary ﬁber, iron, phosphorus, potassium, protein, total
carbohydrate, and zinc.
In this study, subjects consuming EPG were provided with extra
fat in the form of margarine to make up for the caloric deﬁcit cre-
ated by incorporating EPG into the study food products. However,
the results of nutrient analysis suggest that subjects in the EPG 25
and EPG 40 groups were unable to consume all of the additional fat
necessary to fully compensate for the EPG consumed. In addition,
fat intake declined over time in the EPG 25 and EPG 40 groups,
so that the discrepancy in daily fat consumption between these
groups and the control (ordinary triglycerides) group was 1.5–2times as large during the ﬁnal 2 weeks of the study, compared with
the ﬁrst 2 weeks (data not shown).4. Discussion
Overall, retinol (vitamin A), a-tocopherol, and 25-OH D2 (vita-
min D, ergocalciferol) were not signiﬁcantly affected by EPG,
although there were occasionally within-group differences from
baseline, especially early in the study, that reached statistical sig-
niﬁcance. On the other hand, EPG intake was associated with
declines in circulating b-carotene and phylloquinone (vitamin
K1), and an increase in PIVKA-II (proteins induced in vitamin K
absence); 25-OH D3 (vitamin D, cholecalciferol) increased slightly
over time in the EPG groups.
Signiﬁcant declines in b-carotene were seen at each time period,
and the effect was more pronounced in the EPG groups. However, if
the effect was indeed related to EPG intake, it is uncertain why
there was no apparent relationship to EPG concentration (more
severe at 10 g/day and 40 g/day than at 25 g/day).
The bioavailability of carotenoids such as b-carotene can vary
considerably based on the food matrix, concurrent fat intake, and
serum/tissue concentrations. A study that explored, among others,
the fate of b-carotene from carrot purée when administered to
Table 11
Mean change from baseline to the end of the study in blood intact PTH, PT, PTT and RBP.
N Change SD 95% Cl* Comparison to control
Difference 95% Cl p-Value**
Intact PTH
Control 27 6.1 8.5 [3.0, 9.3]
EPG 10 27 4.6 11.4 [0.3, 8.9] 1.59 [6.9, 3.8] 0.5858
EPG 25 23 9.0 11.2 [4.4, 13.6] 2.84 [2.6, 8.3] 0.2548
EPG 40 24 9.1 12.3 [4.2, 14.0] 2.94 [2.8, 8.7] 0.4733
PT (seconds)
Control 27 0.1 0.4 [0.3, 0.1]
EPG 10 27 0 0.3 [0.1, 0.1] 0.11 [0.1, 0.3] 0.5560
EPG 25 24 0.1 0.4 [0, 0.3] 0.22 [0, 0.4] 0.1538
EPG 40 24 0.1 0.3 [0.1, 0.2] 0.18 [0, 0.4] 0.1330
PTT (seconds)
Control 27 1.7 1.7 [2.4, 1.0]
EPG 10 27 1.3 2.1 [2.1, 0.5] 0.42 [0.6, 1.5] 0.3869
EPG 25 24 1.0 1.6 [1.7, 0.4] 0.67 [0.2, 1.6] 0.2905
EPG 40 24 1.3 1.7 [2.0, 0.6] 0.42 [0.5, 1.4] 0.9323
RBP (mg/dL)
Control 24 0.1 0.6 [0.1, 0.4]
EPG 10 23 0.4 0.7 [0.2, 0.7] 0.31 [0.1, 0.7] 0.1222
EPG 25 17 0.2 0.5 [0.1, 0.4] 0.05 [0.3, 0.4] 0.7007
EPG 40 22 0.5 1.0 [0.1, 0.9] 0.34 [0.1, 0.8] 0.1689
Osteocalcin (ng/mL)
Control 25 7.2 11.4 [2.7, 11.7]
EPG 10 26 8.7 9.8 [4.9, 12.5] 1.48 [4.3, 7.3] 0.6242
EPG 25 22 8.1 8.7 [4.4, 11.7] 0.86 [5.0, 6.7] 0.8982
EPG 40 24 7.1 12.8 [2.0, 12.3] 0.07 [6.9, 6.7] 0.9045
Undercarboxylated osteocalcin (ng/mL)
Control 25 0.8 1.8 [0.1, 1.5]
EPG 10 26 1.3 1.8 [0.6, 2.0] 0.50 [0.5, 1.5] 0.3708
EPG 25 22 1.6 1.9 [0.8, 2.4] 0.82 [0.2, 1.9] 0.1029
EPG 40 24 1.1 2.1 [0.3, 2.0] 0.39 [0.7, 1.5] 0.2891
Data shown for subjects evaluable for outcome analysis (see Section 2).
* 95% conﬁdence intervals were used to compare the change from baseline (Day-1) to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
Table 12
Mean change from baseline to the end of the study in blood cholesterol, HDL-C, LDL-C, and triglycerides.
N Change SD 95% CI* Comparison to control
Difference 95% CI p-Value**
Cholesterol (mg/dL)
Control 26 4.9 16.3 [1.4, 11.1]
EPG 10 27 6.9 20.3 [0.8, 14.5] 1.99 [8.0, 11.9] 0.9291
EPG 25 24 3.3 18.8 [10.8, 4.2] 8.18 [17.9, 1.6] 0.1157
EPG 40 24 2.1 17.7 [4.9, 9.2] 2.74 [12.1, 6.7] 0.4091
HDL-Ca (mg/dL)
Control 27 3.2 5.9 [5.4, 0.9]
EPG 10 27 4.9 6.4 [7.3, 2.5] 1.75 [5.0, 1.5] 0.4211
EPG 25 24 7.0 5.9 [9.4, 4.7] 3.90 [7.1, 0.6] 0.0235
EPG 40 25 4.4 5.0 [6.4. 2.5] 1.27 [4.3, 1.7] 0.3181
LDL-Ca (mg/dL)a
Control 27 7.0 16.2 [0.9, 13.1]
EPG 10 24 3.9 16.6 [2.7, 10.5] 3.14 [12.2, 5.9] 0.6234
EPG 25 24 7.6 12.3 [12.5, 2.6] 14.6 [22.6, 6.6] 0.0001
EPG 40 25 3.5 13.0 [8.6, 1.6] 10.6 [18.6. 2.6] 0.0017
Triglycerides (mg/dL)
Control 26 18.7 64.9 [6.2, 43.7]
EPG 10 27 10.6 44.2 [27.3, 6.0] 29.4 [59.2, 0.4] 0.1445
EPG 25 24 0.3 28.7 [11.8, 11.1] 19.0 [47.3, 9.2] 0.6136
EPG 40 24 1.7 26.5 [8.9, 12.3] 17.0 [45.0, 10.9] 0.2032
Data shown for subjects evaluable for outcome analysis (see Section 2).
a Data for HDL-C and LDL-C only available through Day 28.
* 95% conﬁdence intervals were used to compare the change from baseline (Day-1) to Days 14, 28, 42, and 56, and endpoint.
** Two-sided t-tests were used to compare the three EPG groups vs. control at Day 56. Bonferroni correction was used to adjust for multiple comparisons; statistical
signiﬁcance was declared at 0.017 (i.e., 0.05  3) level.
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Table 13
Incidence of adverse events among all study subjects.a
Body system Control (N = 36) EPG 10 (N = 34) EPG 25 (N = 35) EPG 40 (N = 34)
Body as a whole 11 (30.6%) 9 (26.5%) 11 (31.4%) 10 (29.4%)
Central and peripheral nervous system disorders 19 (52.8%) 14 (41.2%) 16 (45.7%) 18 (52.9%)
Headache 19 (52.8%) 14 (41.2%) 16 (45.7%) 17 (50%)
Gastrointestinal (any) 22 (61.1%) 27 (79.4%) 26 (74.3%) 27 (79.4%)
Gastrointestinal (pre-deﬁned) 21 (58.3%) 23 (67.6%) 24 (68.6%) 25 (73.5%)
Abdominal bloating/cramping 13 (36.1%) 15 (44.1%) 20 (57.1%) 17 (50%)
Constipation 8 (22.2%) 8 (23.5%) 8 (22.9%) 9 (26.5%)
Diarrhea 10 (27.8%) 10 (29.4%) 19* (54.3%) 21* (61.8%)
Fecal incontinence 4 (11.1%) 3 (8.8%) 6 (17.1%) 10 (29.4%)
Gas with discharge 4 (11.1%) 8 (23.5%) 11* (31.4%) 14* (41.2%)
Hard stool 5 (13.9%) 10 (29.4%) 4 (11.4%) 5 (14.7%)
Heartburn 5 (13.9%) 7 (20.6%) 4 (11.4%) 3 (8.8%)
Liquid stool 6 (16.7%) 8 (23.5%) 9 (25.7%) 18* (52.9%)
Oily evacuation 2 (5.6%) 6 (17.6%) 12* (34.3%) 14* (41.2%)
Oily spotting 3 (8.3%) 8 (23.5%) 14* (40%) 16* (47.1%)
Oily stool 1 (2.8%) 10* (29.4%) 16* (45.7%) 20* (58.8%)
Passing gas 15 (41.7%) 19 (55.9%) 19 (54.3%) 21 (61.8%)
Soft stool 6 (16.7%) 12 (35.3%) 15* (42.9%) 19* (55.9%)
Urgency of bowel movement 9 (25%) 11 (32.4%) 15 (42.9%) 19 (55.9%)
Gastrointestinal system disorders (other) 15 (41.7%) 14 (41.2%) 11 (31.4%) 14 (41.2%)
Abdominal pain 3 (8.3%) 2 (5.9%) 1 (2.9%) 6 (17.6%)
Dyspepsia 3 (8.3%) 2 (5.9%) 3 (8.6%) 0
Eructation 0 0 0 1 (2.9%)
Gastrointestinal disorder, nonspeciﬁc 0 1 (2.9%) 0 0
Gastroesophageal reﬂux 0 0 0 1 (2.9%)
Hemorrhoids 0 1 (2.9%) 0 0
Mouth dry 0 1 (2.9%) 0 0
Nausea 4 (11.1%) 5 (14.7%) 5 (14.3%) 3 (8.8%)
Tooth ache 0 2 (5.9%) 2 (5.7%) 1 (2.9%)
Tooth caries 0 0 1 (2.9%) 1 (2.9%)
Vomiting 7 (19.4%) 5 (14.7%) 3 (8.6%) 6 (17.6%)
Hearing and vestibular disorders 0 1 (2.9%) 0 1 (2.9%)
Metabolic and nutritional disorders 1 (2.8%) 0 1 (2.9%) 2 (5.9%)
Musculoskeletal system disorders 2 (5.6%) 1 (2.9%) 0 2 (5.9%)
Neoplasm 1 (2.8%) 0 0 0
Platelet, bleeding and clotting disorders 0 0 1 (2.9%) 0
Psychiatric disorders 1 (2.8%) 1 (2.9%) 0 3 (8.8%)
Reproductive disorders, female 6 (16.7%) 4 (11.8%) 5 (14.3%) 3 (8.8%)
Resistance mechanism disorders 3 (8.3%) 0 4 (11.4%) 1 (2.9%)
Respiratory system disorders 19 (52.8%) 20 (58.8%) 12 (34.3%) 14 (41.2%)
Rhinitis 14 (38.9%) 12 (35.3%) 9 (25.7%) 8 (23.5%)
Secondary terms 1 (2.8%) 0 1 (2.9%) 1 (2.9%)
Skin and appendages disorders 3 (8.3%) 2 (5.9%) 2 (5.7%) 5 (14.7%)
Urinary system disorders 2 (5.6%) 0 4 (11.4%) 2 (5.9%)
Vascular (extracardiac disorders) 0 1 (2.9%) 1 (2.9%) 0
Vision disorders 1 (2.8%) 0 0 0
a Includes 14 pre-deﬁned gastrointestinal symptoms and others by body system and World Health Organization (WHO) terms. If a subject experienced more than one
episode of an adverse event, he/she was counted only once for the total number of subjects experiencing that adverse event.
* Statistically signiﬁcant difference vs. control (p 6 0.05), Fisher’s Exact Test with pairwise comparisons.
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stomach and duodenal contents, that the stomach initiates the
transfer of carotenoids from the food matrix to the fat phase of a
meal, but that the proportion of carotenoids recovered in the
micellar phase of the duodenum is very low (<7%) (Tyssandier
et al., 2003).
It is possible that the apparent effect of EPG on circulating b-
carotene was related to the lower dietary fat intake among subjects
receiving EPG. As previously mentioned, subjects might not have
consumed all of the additional fat necessary to fully compensate
for what EPG displaced in the diet. In this case, as a lipid-like mate-
rial, EPG might have affected the absorption of these nutrients
strictly through physicochemical processes, acting as a lipid ‘‘sink’’
during transit in the gastrointestinal tract. Substances known to
reduce the bioavailability of carotenoids are lipid-lowering agents
such as cholestyramine and probucol (Elinder et al., 1995), nonab-
sorbable fat substitutes such as sucrose polyester (olestra) (Peters
et al., 1997; Schlagheck et al., 1997; Tulley et al., 2005; Neuhouser
et al., 2006), plant sterol-enriched margarines (Gylling et al., 1999;Law, 2000; Hendriks et al., 2003), and dietary ﬁber supplementa-
tion (Rock and Swendseid, 1992). No dietary reference intakes
(DRIs) per se have been proposed by the Institute of Medicine for
carotenoids, although existing recommendations for increased
consumption of carotenoid-rich fruits and vegetables are sup-
ported (IOM, 2000).
In experimental animal studies, EPG has been associated with
declines in some fat-soluble vitamins, including vitamin D, but
with no clinical signs of vitamin deﬁciency (unpublished data). In
the present study, dietary EPG was not associated with any effects
on circulating 25-OH-D2 levels. At the end of the study, 25-OH-D3
levels in the EPG 25 and EPG 40 groups were lower than baseline
(also in EPG 25 at Day 42). However, it is difﬁcult to determine
whether EPG had any effect on circulating 25-OH-D3 levels in this
study for a number of reasons. First, the control group had an
abnormal rise in circulating 25-OH-D3 to levels that, at times, far
exceeded baseline levels. This is an unexpected ﬁnding, since the
study was conducted in the winter in Chicago, Illinois, USA, when
endogenous 25-OH-D3 synthesis would have been extremely low,
M.H. Davidson, D.H. Bechtel / Regulatory Toxicology and Pharmacology 70 (2014) S143–S157 S157and the dietary intakes of 25-OH-D3 by the control and EPG groups
(from prepared meals consumed at the study facility) would have
been comparable. As a result of this unusual occurrence, the con-
trol group showed a greater change (increase) from baseline than
the EPG groups, which had only marginal increases/decreases from
baseline. Secondly, the within-group differences from baseline
were not statistically signiﬁcant for any EPG group; in the EPG
10 group, 25-OH D3 was consistently higher than baseline after
Day 14. Therefore, any possible effect of EPG on circulating 25-
OH-D3 in this study was very small, evident only at 25 g/day and
greater, and with no other clinical manifestation.
Whereas there was no change or a slight increase from baseline
circulating phylloquinone levels in the control, EPG intake was
associated with a slight decline across all groups. However, the
declines did not exceed 0.1 ng/mL and were not statistically signif-
icant within any of the individual groups; statistical signiﬁcance
was observed only when the differences within each EPG group
were compared to the differences (none or positive) in the control.
In experimental animal studies, EPG has not been found to have
any effect on vitamin K (unpublished data).
By the end of the study, the levels of proteins induced in vita-
min K absence (PIVKA-II) had increased signiﬁcantly in the EPG
25 and EPG 40 groups, compared to the control; in the EPG 10
group, the difference from baseline was comparable to the differ-
ence from baseline in the control. Combined with the phylloqui-
none results, these data suggest that EPG might have affected the
synthesis of vitamin K-dependent clotting factors to some extent,
but the changes were small, and there was no indication of any
clinical manifestation. The changes in clotting parameters (PT
and PTT) from baseline to the end of the study were comparable
between the control and EPG groups.
With the exception of gastrointestinal discomfort, all adverse
events reported by subjects in this study were considered unre-
lated to EPG. Seven of the 14 pre-deﬁned gastrointestinal adverse
events (gas with discharge; diarrhea; oily spotting; oily evacua-
tion; oily stool; liquid stool; soft stool) were reported more fre-
quently by subjects receiving 25 or 40 g/day of EPG, especially
females. In general, the incidence and duration of these symptoms
correlated with EPG dietary concentration and suggest that
10 g/day of EPG was reasonably well tolerated.Conﬂict of interest statement
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